J Latorre1, J M Moreno-Navarrete1,2, J M Mercader3, M Sabater1,2, Ò Rovira1, J Gironès4, W Ricart1,2, J M Fernández-Real1,2, F J Ortega1,2. 1. Department of Diabetes, Endocrinology and Nutrition (UDEN), Institut d'Investigació Biomédica de Girona (IdIBGi), Hospital of Girona 'Dr Josep Trueta' Carretera de França s/n, Girona, Spain. 2. CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn) and Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 3. Joint BSC-CRG-IRB Research Program in Computational Biology, Barcelona Supercomputing Center, Barcelona, Spain. 4. Department of Surgery, Hospital Dr. Josep Trueta of Girona, Girona, Spain.
Abstract
BACKGROUND/ OBJECTIVE: Many controversies regarding the association of liver miRNAs with obesity and nonalcoholic fatty liver diseases (NAFLD) call for additional validations. This study sought to investigate variations in genes and hepatic miRNAs in a sample of obese patients with or without NAFLD and human hepatocytes (HH). SUBJECTS/ METHODS: A total of 60 non-consecutive obese women following bariatric surgery were recruited. Subjects were classified as NAFLD (n=17), borderline (n=24) and controls (n=19) with normal enzymatic profile, liver histology and ultrasound assessments. Profiling of 744 miRNAs was performed in 8 obese women with no sign of hepatic disease and 11 NAFLD patients. Additional validation and expression of genes related to de novo fatty acid (FA) biosynthesis, uptake, transport and β-oxidation; glucose metabolism, and inflammation was tested in the extended sample. Induction of NAFLD-related genes and miRNAs was examined in HepG2 cells and primary HH treated with palmitic acid (PA), a combination of palmitate and oleic acid, or high glucose, and insulin (HG) mimicking insulin resistance in NAFLD. RESULTS: In the discovery sample, 14 miRNAs were associated with NAFLD. Analyses in the extended sample confirmed decreased miR-139-5p, miR-30b-5p, miR-122-5p and miR-422a, and increased miR-146b-5p in obese subjects with NAFLD. Multiple linear regression analyses disclosed that NAFLD contributed independently to explain miR-139-5p (P=0.005), miR-30b-5p (P=0.005), miR-122-5p (P=0.021), miR-422a (P=0.007) and miR-146a (P=0.033) expression variance after controlling for confounders. Decreased miR-122-5p in liver was associated with impaired FA usage. Expression of inflammatory and macrophage-related genes was opposite to decreased miR-30b-5p, miR-139-5p and miR-422a, whereas increased miR-146b-5p was associated with FABP4 and decreased glucose metabolism and FA mobilization. In partial agreement, PA (but not HG) led to decreased miR-139-5p, miR-30b-5p, miR-422a and miR-146a in vitro, in parallel with increased lipogenesis and FA transport, decreased glucose metabolism and diminished FA oxidation. CONCLUSION: This study confirms decreased liver glucose and lipid metabolism but increased FA biosynthesis coupled with changes in five unique miRNAs in obese patients with NAFLD.
BACKGROUND/ OBJECTIVE: Many controversies regarding the association of liver miRNAs with obesity and nonalcoholic fatty liver diseases (NAFLD) call for additional validations. This study sought to investigate variations in genes and hepatic miRNAs in a sample of obesepatients with or without NAFLD and human hepatocytes (HH). SUBJECTS/ METHODS: A total of 60 non-consecutive obesewomen following bariatric surgery were recruited. Subjects were classified as NAFLD (n=17), borderline (n=24) and controls (n=19) with normal enzymatic profile, liver histology and ultrasound assessments. Profiling of 744 miRNAs was performed in 8 obesewomen with no sign of hepatic disease and 11 NAFLD patients. Additional validation and expression of genes related to de novo fatty acid (FA) biosynthesis, uptake, transport and β-oxidation; glucose metabolism, and inflammation was tested in the extended sample. Induction of NAFLD-related genes and miRNAs was examined in HepG2 cells and primary HH treated with palmitic acid (PA), a combination of palmitate and oleic acid, or high glucose, and insulin (HG) mimicking insulin resistance in NAFLD. RESULTS: In the discovery sample, 14 miRNAs were associated with NAFLD. Analyses in the extended sample confirmed decreased miR-139-5p, miR-30b-5p, miR-122-5p and miR-422a, and increased miR-146b-5p in obese subjects with NAFLD. Multiple linear regression analyses disclosed that NAFLD contributed independently to explain miR-139-5p (P=0.005), miR-30b-5p (P=0.005), miR-122-5p (P=0.021), miR-422a (P=0.007) and miR-146a (P=0.033) expression variance after controlling for confounders. Decreased miR-122-5p in liver was associated with impaired FA usage. Expression of inflammatory and macrophage-related genes was opposite to decreased miR-30b-5p, miR-139-5p and miR-422a, whereas increased miR-146b-5p was associated with FABP4 and decreased glucose metabolism and FA mobilization. In partial agreement, PA (but not HG) led to decreased miR-139-5p, miR-30b-5p, miR-422a and miR-146a in vitro, in parallel with increased lipogenesis and FA transport, decreased glucose metabolism and diminished FA oxidation. CONCLUSION: This study confirms decreased liver glucose and lipid metabolism but increased FA biosynthesis coupled with changes in five unique miRNAs in obesepatients with NAFLD.
Authors: Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore Journal: Proc Natl Acad Sci U S A Date: 2006-08-02 Impact factor: 11.205
Authors: Shu-Hao Hsu; Bo Wang; Janaiah Kota; Jianhua Yu; Stefan Costinean; Huban Kutay; Lianbo Yu; Shoumei Bai; Krista La Perle; Raghu R Chivukula; Hsiaoyin Mao; Min Wei; K Reed Clark; Jerry R Mendell; Michael A Caligiuri; Samson T Jacob; Joshua T Mendell; Kalpana Ghoshal Journal: J Clin Invest Date: 2012-07-23 Impact factor: 14.808
Authors: Francisco J Ortega; Josep M Mercader; José María Moreno-Navarrete; Oscar Rovira; Ester Guerra; Eduardo Esteve; Gemma Xifra; Cristina Martínez; Wifredo Ricart; Jennifer Rieusset; Sophie Rome; Monika Karczewska-Kupczewska; Marek Straczkowski; José Manuel Fernández-Real Journal: Diabetes Care Date: 2014-01-29 Impact factor: 19.112
Authors: Francisco José Ortega; María Moreno; Josep María Mercader; José María Moreno-Navarrete; Núria Fuentes-Batllevell; Mònica Sabater; Wifredo Ricart; José Manuel Fernández-Real Journal: Clin Epigenetics Date: 2015-04-24 Impact factor: 6.551
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: Nadia Saadat; Muraly Puttabyatappa; Venkateswaran R Elangovan; John Dou; Joseph N Ciarelli; Robert C Thompson; Kelly M Bakulski; Vasantha Padmanabhan Journal: Endocrinology Date: 2022-01-01 Impact factor: 4.736
Authors: Jordi Mayneris-Perxachs; Marina Cardellini; Lesley Hoyles; Jèssica Latorre; Francesca Davato; José Maria Moreno-Navarrete; María Arnoriaga-Rodríguez; Matteo Serino; James Abbott; Richard H Barton; Josep Puig; Xavier Fernández-Real; Wifredo Ricart; Christopher Tomlinson; Mark Woodbridge; Paolo Gentileschi; Sarah A Butcher; Elaine Holmes; Jeremy K Nicholson; Vicente Pérez-Brocal; Andrés Moya; Donald Mc Clain; Rémy Burcelin; Marc-Emmanuel Dumas; Massimo Federici; José-Manuel Fernández-Real Journal: Microbiome Date: 2021-05-07 Impact factor: 14.650
Authors: Oriol Juanola; Sebastián Martínez-López; Rubén Francés; Isabel Gómez-Hurtado Journal: Int J Environ Res Public Health Date: 2021-05-14 Impact factor: 3.390